The central technical innovation that unlocked this field is the DdCBE system, a twin adenine-associated protein base editor in which two halves of a bacterial toxin-derived deaminase are each fused to a mitochondria-targeting sequence. When the two halves are brought together on opposite strands of the mitochondrial genome, the reconstituted enzyme converts one DNA base into another without making a double-strand break. A companion approach, termed mitoTALED, applies the same split-enzyme logic to adenine base conversion, and subsequent iterations have expanded the repertoire of accessible edits. Because these systems bypass the requirement for guide RNAs entirely, they sidestep the mitochondrial RNA import problem that stymied conventional CRISPR-based strategies for over a decade. The result is a toolset that can, in principle, install or reverse any transition mutation across the circular mitochondrial chromosome, opening the door to precise manipulation of a genome that carries pathogenic variants underlying a wide range of neuromuscular, metabolic, and neurodegenerative disorders.

The review emphasizes that generating a disease model is not as simple as pointing an editor at a mutation. Target selection demands careful attention to several constraints that the authors organize into a coherent decision framework. First, because the editors operate on specific base conversions, only a subset of the hundreds of known pathogenic mitochondrial DNA mutations can be faithfully recapitulated with current chemistry. Second, the editing window, the narrow stretch of DNA over which the deaminase acts once the two editor halves dock, must align with the position of the intended variant; off-target conversions within the window can create confounding mutations. Third, strand bias is a recurring technical reality, with editing efficiencies differing substantially depending on which mitochondrial DNA strand the deaminase ultimately acts upon, a consequence of the asymmetric architecture of the split-enzyme design. Fourth, the sequence context surrounding a target site, including neighboring nucleotides and local secondary structure, can dramatically modulate editing outcomes, making empirical validation at every candidate locus unavoidable.

Cross-species conservation emerges as another decisive consideration. Many mitochondrial disease models are pursued in mice, yet the murine mitochondrial genome differs from the human one at key positions, meaning that a mutation that is pathogenic in patients may not be directly installable at the orthologous site in an animal. The authors discuss how researchers must weigh the fidelity of a candidate model against the biological questions it is meant to answer, sometimes choosing a homologous but non-identical variant, or turning to alternative model organisms whose mitochondrial genomes more closely match the human sequence. This tension between practicality and physiological relevance is a recurring theme throughout the review, and the authors argue that rigorous justification of target selection is essential if edited models are to yield interpretable conclusions about human disease mechanisms.

Once an edited model has been generated, validation becomes the next hurdle, and the review proposes a three-tiered strategy operating at the functional, molecular, and organismal levels. At the molecular level, techniques such as ultra-deep amplicon sequencing quantify the fraction of mitochondrial genomes carrying the intended edit, a critical measurement given that heteroplasmy, the coexistence of mutated and wild-type mitochondrial DNA within a single cell, often determines whether a pathogenic variant crosses the biochemical threshold that triggers cellular dysfunction. At the functional level, the downstream consequences of an edit must be demonstrated: defects in respiratory chain complex activity, altered oxygen consumption rates, changes in membrane potential, shifts in ATP production, and activation of the mitochondrial unfolded protein response all serve as readouts that connect genotype to bioenergetic phenotype. At the organismal level, edited animal models must recapitulate the clinical features of the corresponding human condition, including tissue-specific pathology, age of onset, and inheritance patterns, before they can be trusted as platforms for drug discovery or preclinical testing.

The therapeutic dimension of the field is where momentum has been most striking. Rather than installing mutations, several recent studies have deployed mitochondrial base editors to reverse them, correcting pathogenic variants in vivo and rescuing disease phenotypes in animal models. The review highlights this therapeutic rescue work as proof of principle that the same enzymatic machinery used to build models can, with appropriate delivery vehicles, reach the mitochondria of affected tissues and shift heteroplasmy away from the mutant genome. The implications for mitochondrial medicine are considerable. Current therapeutic options for mitochondrial DNA diseases, which include dietary supplementation, exercise regimens, and in select cases genetic therapies aimed at reducing mutant genome load, address symptoms rather than the underlying genetic lesion. A base editor that permanently converts a pathogenic mutation back to the wild-type sequence offers something closer to a genuine cure, at least in principle.

Safety, however, remains a central preoccupation, and the authors devote sustained attention to the trade-off between editing efficiency and unintended effects. Off-target editing within the mitochondrial genome, where the deaminase acts at sequences resembling the intended target, has been documented for several editor architectures, and more recent work has raised the possibility of off-target effects in the nuclear genome as well, since components of the editor can occasionally be mislocalized to the nucleus. Prolonged expression of the editor increases the cumulative risk of such events, prompting interest in delivery strategies that limit exposure time, including mRNA-based delivery and engineered variants with narrower editing windows. The review frames this as an optimization problem: editors must be efficient enough to shift heteroplasmy to sub-threshold levels in a meaningful fraction of mitochondria, yet restrained enough that collateral edits, whether mitochondrial or nuclear, remain acceptably rare. Balancing these competing demands, the authors argue, will determine whether mitochondrial base editing can transition from laboratory tool to clinical platform.

The broader significance of this synthesis lies in its timing. Mitochondrial diseases collectively affect roughly one in several thousand live births, and no cure exists for the majority of the more than 300 pathogenic point mutations cataloged in human populations. The inability to manipulate mitochondrial DNA precisely has been a structural limitation of the entire field, forcing researchers to rely on patient-derived cells with unpredictable heteroplasmy, cybrid models with uncertain fidelity, and transmitochondrial animal lines generated through cumbersome techniques such as cytoplasmic transfer into embryos. Programmable base editors change this calculus. A researcher can now specify a mutation, install it at will in a cell line or an animal, and study its consequences under controlled conditions, then use the same or a complementary editor to erase it. That symmetry between disease modeling and therapeutic correction, the review argues, is the defining feature of the current era.

The work was conducted by teams based at Seoul National University and Korea University College of Medicine, with Youngho Kim affiliated with Edgene, Inc., a company whose involvement signals growing commercial interest in mitochondrial editing therapeutics. Hyunji Lee, the corresponding author, has filed patent applications related to the technology, including international filings under WO2022060185A1 and PCT/KR2021/012872 and a Korean patent application, underscoring that the intellectual property landscape around mitochondrial base editing is actively forming. The research was supported by grants from the Korea Institute for Advancement of Technology funded by the Ministry of Trade, Industry and Energy, and by the National Research Foundation of Korea through multiple programs funded by the Ministry of Science and ICT. Figures in the article were created with BioRender, and the paper was published open access under a Creative Commons license, with Claudia Feng serving as the primary editor during peer review.

As the field moves forward, the framework laid out in this review, spanning target selection, cross-species validation, window engineering, strand-bias correction, and staged functional testing, is likely to become a reference standard for laboratories entering the mitochondrial editing space. The remaining challenges are formidable: delivering editors efficiently to the nervous system and muscle, the tissues most ravaged by mitochondrial disease; achieving durable and tissue-appropriate heteroplasmy shifts; and excluding off-target activity with the rigor that regulatory authorities will demand. Yet the trajectory is unmistakable. Within a few short years, mitochondrial DNA has gone from an uneditable genomic outpost to a programmable therapeutic target, and the studies reviewed here, culminating in demonstrated disease rescue in animal models, suggest that the first clinical applications of mitochondrial base editing may be approaching faster than many in the field once thought possible.

Mitochondria, the cellular power plants inseparable from the human biological fabric for over 1.5 billion years, carry their own unique DNA. This mitochondrial genome governs the production of essential proteins critical for cellular energy generation. However, mtDNA is characterized by a notably high mutation rate, owing primarily to imperfect repair mechanisms within mitochondria. Such mutations accumulate over time and are implicated in a spectrum of debilitating conditions, including inherited mitochondrial disorders, neurodegenerative diseases, cancer, and the physiological decline associated with aging.

For decades, the scientific community has grappled with the challenge of deciphering the intricate effects of specific mitochondrial DNA mutations. Traditional methodologies, heavily reliant on labor-intensive and time-consuming generation of one mouse model per mutation, have hindered the comprehensive study of mitochondrial pathophysiology. It was this bottleneck that motivated Weiwei Fan, PhD, during his doctoral research, to conceive the initial version of the stem-cell based mitochondrial DNA mutagenesis platform.

Building upon this foundation, Fan and his colleagues have dramatically refined the system to substantially increase throughput. By employing mitochondrial DNA polymerase to induce random mutations in mtDNA and introducing these mutated genomes into stem cells, the platform facilitates the rapid creation of numerous mutant lines. These stem cells integrate with mouse embryos, generating animals each harboring a unique mitochondrial mutation, thereby providing a living framework to investigate genotype-phenotype relationships with unparalleled efficiency.

The research team successfully constructed a comprehensive library of 155 mitochondrial DNA mutant cell lines. Each line exhibits distinct mitochondrial functional impairments, mimicking the diverse array of mutations observed in human mitochondrial diseases. This resource not only reflects the heterogeneity of known pathogenic mtDNA mutations but also includes variants that may arise through environmental stresses or the natural aging process, broadening the scope of applicability.

Verification of the platform’s capability was demonstrated through the production of viable mutant mice, allowing for in vivo analysis of the impact of individual mutations on development and physiology. Intriguingly, the researchers observed a direct correlation between mitochondrial function and early embryonic development, underscoring the critical energy requirements necessary during this formative stage and suggesting that mitochondrial performance sets a vital threshold for normal development.

Mitochondrial disorders, although diverse in manifestation, commonly affect high-energy demanding organs such as the brain and heart. The phenotypic outcomes include debilitating symptoms like muscle weakness, sensory deficits, and neurological impairments. The novel platform promises to expedite the generation of precise animal models reflecting these conditions, offering an invaluable tool to dissect pathogenic mechanisms and test potential interventions systematically.

Dr. Ronald Evans, senior author and a distinguished molecular biologist at the Salk Institute, emphasizes the transformational potential of this technology. He notes that prior limitations in modeling the broad spectrum of mtDNA mutations have constrained therapeutic innovation. The ability to replicate the diversity of mitochondrial mutations in a rapid, scalable manner offers a new frontier for investigating disease pathways and accelerating drug discovery.

Beyond inherited mitochondrial diseases, the platform’s applicability extends to understanding mitochondrial dysfunction in widespread pathological contexts, including oncogenesis and the aging process. Given mitochondria’s centrality to cellular metabolism and apoptosis, insights gained from these models could unlock novel approaches to ameliorate or even reverse disease states linked to mitochondrial decline.

Further enhancing the translational potential of this research is the planned progression toward human cellular models that more accurately replicate human physiology than mouse analogues. Such models would significantly enhance the relevance of preclinical studies and facilitate the development of personalized therapies targeting mitochondrial dysfunction.

The study, recently published in the esteemed journal Proceedings of the National Academy of Sciences, represents a collaborative effort among Salk Institute researchers including Lillian Crossley, Hunter Robbins, Mingxiao He, Yang Dai, Morgan Truitt, Annette Atkins, and Michael Downes, alongside contributions from Tae Gyu Oh of the University of Oklahoma.

Support for this research was provided through an array of sources spanning federal funding bodies such as the National Institutes of Health and the Department of the Navy, to private foundations including the Larry L. Hillblom Foundation and the Wu Tsai Human Performance Alliance. Such robust backing underscores the significance recognized by the scientific and philanthropic communities alike.

As mitochondrial biology continues to unveil its complexities, innovations like this scalable embryonic stem cell platform catalyze not only deeper understanding but also the urgent development of therapeutics. This breakthrough ushers in a new era where mitochondrial diseases and related dysfunctions may finally be confronted with targeted, effective strategies born of precise genetic modeling.

Subject of Research: Generation of mitochondrial DNA mutant mice using a scalable embryonic stem cell–based platform for studying mitochondrial disorders and dysfunction.

Article Title: A scalable embryonic stem cell–based platform for efficient generation of mitochondrial DNA mutant mice

News Publication Date: April 10, 2026

Web References: https://doi.org/10.1073/pnas.2535453123

Image Credits: Salk Institute

Keywords: Mitochondrial DNA, mitochondrial diseases, stem cells, embryonic development, mouse models, genetic mutations, mitochondrial dysfunction, therapeutic development, cellular metabolism, aging, cancer, molecular genetics